Andexanet alfa与四因子凝血酶原复合物浓缩物逆转阿哌沙班或利伐沙班相关颅内出血的比较
本研究为回顾性病历分析,纳入2016年6月至2020年12月佛罗里达州中部多中心医疗系统及一家独立教学医院收治的109例颅内出血患者,患者年龄≥18岁,入院前服用阿哌沙班或利伐沙班,影像学证实颅内出血,并接受Andexanet alfa(AA组47例,43.1%)或四因子凝血酶原复合物浓缩物(4F-PCC组62例,56.9%)逆转治疗。主要终点为基于ISTH标准评估的优良止血率,AA组71.1%(27例) vs 4F-PCC组70.7%(41例),差异无统计学意义(p=1,调整后p=0.654)。次要终点包括血肿体积变化、血栓栓塞事件、住院死亡率及治疗总费用,除总费用外均无统计学显著差异。作者认为,基于本研究证据,尚不足以推荐AA优于4F-PCC用于此类患者。
要点
- 在阿哌沙班或利伐沙班相关颅内出血患者中,AA组优良止血率为71.1%(27例),4F-PCC组为70.7%(41例),差异无统计学意义(p=1,调整后p=0.654)。
- 逆转治疗后12-24小时血肿体积中位百分比变化在AA组为0 [-0.17--0.24],4F-PCC组为0 [-0.021-0.29],差异无统计学意义(p=0.439,调整后p=0.601)。
- 血栓栓塞事件发生率AA组8.5%(4例) vs 4F-PCC组9.7%(6例),差异无统计学意义(p=1,调整后p=0.973)。
- 住院死亡率AA组34.0%(16例) vs 4F-PCC组21.0%(13例),差异无统计学意义(p=0.134,调整后p=0.283)。
- 治疗总费用AA组为$23,602,4F-PCC组为$6692,差异有统计学意义。
适用人群与场景
- 年龄≥18岁,入院前服用阿哌沙班或利伐沙班,影像学证据显示颅内出血(创伤性或自发性),并接受AA或4F-PCC作为逆转剂的患者。
- 研究场所为佛罗里达州中部多中心医疗系统及一家独立教学医院,时间范围为2016年6月至2020年12月。
研究设计与关键结果
- 研究类型为回顾性病历分析,共纳入109例患者,AA组47例(43.1%),4F-PCC组62例(56.9%)。
- 主要终点优良止血率:AA组71.1%(27例) vs 4F-PCC组70.7%(41例),p=1,调整年龄、ICH评分、区域占位效应和中线移位后p=0.654。
- 血肿体积从基线至逆转治疗后12-24小时的中位百分比变化:AA组0 [-0.17--0.24] vs 4F-PCC组0 [-0.021-0.29],p=0.439,调整后p=0.601。
- 血栓栓塞事件发生率:AA组8.5%(4例) vs 4F-PCC组9.7%(6例),p=1,调整后p=0.973。
- 住院死亡率:AA组34.0%(16例) vs 4F-PCC组21.0%(13例),p=0.134,调整后p=0.283。
- 治疗总费用:AA组$23,602 vs 4F-PCC组$6692,差异有统计学意义。
证据类型、等级与局限
- 证据类型:回顾性病历分析。
- 作者结论:基于本研究证据,尚不足以推荐AA优于4F-PCC用于阿哌沙班或利伐沙班相关颅内出血患者。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于本研究证据,尚不足以推荐AA优于4F-PCC用于阿哌沙班或利伐沙班相关颅内出血患者。
- 本研究显示AA与4F-PCC在止血效果、血肿体积变化、血栓栓塞事件及住院死亡率方面无统计学显著差异,但AA治疗总费用显著更高($23,602 vs $6692)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Existing research recommends either andexanet alfa (AA) or four-factor prothrombin complex concentrate (4F-PCC) as an antidote for major bleeding events due to apixaban or rivaroxaban. Currently, there is limited published research that directly compares the risks and benefits of the two agents in patients with oral factor Xa inhibitor related traumatic and spontaneous intracerebral hemorrhages. Additional head-to-head data is needed to support favoring either AA or 4F-PCC when it comes to efficacy, safety, and cost.
METHODS: A retrospective chart review was conducted to assess patients admitted to a multi-center healthcare system and a stand-alone teaching hospital in central Florida from June 2016 to December 2020. Patients included in the study were at least 18 years of age, taking apixaban or rivaroxaban prior to admission, had radiographical evidence of an intracranial hemorrhage, and received either AA or 4F-PCC as a reversal agent. The primary outcome analyzed was the level of excellent hemostasis achieved, based on a standardized rating system for effective hemostasis defined by the International Society of Thrombosis and Hemostasis (ISTH), after administration of AA or 4F-PCC. Secondary outcomes analyzed included changes in the initial hemorrhage volume as reported on computed tomography (CT) scan and at 12 to 24 h post treatment, rate of thromboembolic events, rate of inpatient mortality, and total cost of treatment after AA or 4F-PCC administration.
RESULTS: A total of 109 patients were included in the study with 47 in the AA group (43.1%) and 62 in the 4F-PCC group (56.9%). There were no statistically significant differences between AA and 4F-PCC in terms of the primary and secondary outcomes with the exception of total cost of treatment. The level of excellent hemostasis achieved after reversal administration of AA was seen in 27 patients (71.1%) and 41 patients (70.7%) after 4F-PCC administration (p = 1, p adjusted = 0.654 after controlling for age, ICH score, regional mass effect, and midline shift). There was no statistically significant difference in the median percentage change in hemorrhagic volume from baseline to 12-24 h after reversal treatment (0 [-0.17--0.24] vs. 0 [-0.021-0.29], p = 0.439, adjusted p = 0.601) in the AA and 4F-PCC groups, respectively. The total incidence of thromboembolic events (4 [8.5%] vs. 6 [9.7%], p = 1, adjusted p = 0.973) and rate of inpatient mortality was similar between the two groups (16 [34.0%] vs. 13 [21.0%], p = 0.134, adjusted p = 0.283). A statistically significant difference was observed with the total cost of reversal treatment: $23,602 for treatment with AA and $6692 for treatment with 4F-PCC.
CONCLUSIONS: No statistically significant differences were identified in primary or secondary outcomes between the two agents with the exception of total treatment cost. There is insufficient evidence based on this study to recommend AA over 4F-PCC for patients with intracranial hemorrhages associated with the use of apixaban or rivaroxaban.
参考来源
- Pham H, Medford WG, Horst S, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. Am J Emerg Med. 2022. PMID: 35272069. doi:10.1016/j.ajem.2022.02.029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。